Update on a real-world study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide

"Update on a real-world study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide." Scandinavian Journal of Urology, 54(3), pp. 263–264

Disclosure statement

Mohammed Alghazali has received personal fees from Astellas Pharma a/s during the conduct of the study. Annica Löfgren was a study coordinator in a study funded by Astellas Pharma a/s. Newton Cheng is an employee at IQVIA Solutions a/s and reports receiving grants from Astellas Pharma a/s during the conduct of this study. Karin Fagerlund is an employee at Astellas Pharma a/s and the medical adviser/study lead for this study. Anders Bjartell has received funding from Astellas Pharma a/s.

Additional information

Funding

This study was funded by Astellas Pharma a/s – Nordic Operation, part of Astellas Pharma Inc and Pfizer Inc, the co-developers of enzalutamide. The database was funded by Skåne University Hospital. Editorial assistance was provided by Beatrice Vetter-Ceriotti, PhD, and Jane Beck from Complete HealthVizion, funded by the study sponsors.